For decades, gene therapy lived on the edge of possibility. Scientists promised cures at the molecular level. Investors poured billions into biotech startups. Yet progress often felt incremental—punctuated by setbacks, safety concerns, and regulatory hesitation. Then, 2026 changed the tempo. This year marks a structural shift in how gene therapy is developed, delivered, and scaled.…